Sarepta Therapeutics Inc. logo

Sarepta Therapeutics Inc. (SRPT)

Market Closed
25 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
11. 93
-0.95
-7.38%
$
1.31B Market Cap
- P/E Ratio
0% Div Yield
13,664,870 Volume
-6.99 Eps
$ 12.88
Previous Close
Day Range
11.12 12.29
Year Range
10.42 150.48
Want to track SRPT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 5 days

Summary

SRPT closed today lower at $11.93, a decrease of 7.38% from yesterday's close, completing a monthly decrease of -11.24% or $1.51. Over the past 12 months, SRPT stock lost -90.28%.
SRPT is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.1%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

SRPT Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys

US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.

Reuters | 1 hour ago
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.

Seekingalpha | 3 days ago
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.

Zacks | 3 days ago

Sarepta Therapeutics Inc. Dividends

SRPT is not paying dividends to its shareholders.

Sarepta Therapeutics Inc. Earnings

6 Aug 2025 (In 1 week) Date
0.94
Cons. EPS
-
EPS
30 Jul 2025 (In 5 days) Date
0.7
Cons. EPS
-
EPS
29 Apr 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
2.06
Cons. EPS
1.9
EPS
6 Nov 2024 Date
-
Cons. EPS
0.34
EPS
SRPT is not paying dividends to its shareholders.
6 Aug 2025 (In 1 week) Date
0.94
Cons. EPS
-
EPS
30 Jul 2025 (In 5 days) Date
0.7
Cons. EPS
-
EPS
29 Apr 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
2.06
Cons. EPS
1.9
EPS
6 Nov 2024 Date
-
Cons. EPS
0.34
EPS

Sarepta Therapeutics Inc. (SRPT) FAQ

What is the stock price today?

The current price is $11.93.

On which exchange is it traded?

Sarepta Therapeutics Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is SRPT.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 1.31B.

What is the earnings per share?

The EPS is 0.7.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Sarepta Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Sarepta Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Douglas S. Ingram CEO
NASDAQ (NGS) Exchange
803607100 Cusip
US Country
1,372 Employees
- Last Dividend
12 Jul 2012 Last Split
3 Jun 1997 IPO Date

Overview

Sarepta Therapeutics, Inc. is a forefront commercial-stage biopharmaceutical entity devoted to pioneering RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities aimed at the treatment of rare diseases. Since its inception in 1980, the company has established itself as an innovator in the field, located in the renowned biotech hub of Cambridge, Massachusetts. Through strategic collaborations and license agreements with prestigious institutions like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, and universities such as Florida and Duke, as well as with dynamic biotech innovators like Dyno Therapeutics, Hansa Biopharma, Genethon, and StrideBio, Sarepta Therapeutics has pushed the boundaries of genetic medicine, focusing on diseases with significant unmet medical needs.

Products and Services

  • EXONDYS 51 Injection
  • A groundbreaking therapy designed to treat Duchenne muscular dystrophy (Duchenne) in patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. This therapy represents a beacon of hope for those affected by this rare genetic condition, offering a targeted approach to manage its progression.

  • VYONDYS 53
  • Aimed specifically at Duchenne patients with a confirmed mutation of the dystrophin gene that can benefit from exon 53 skipping. VYONDYS 53 exemplifies the company's tailor-made approach to treating genetic disorders, addressing the needs of a specific subset of the Duchenne community.

  • AMONDYS 45
  • This therapeutic solution serves the Duchenne community by targeting patients with specific confirmed mutations of the dystrophin gene. AMONDYS 45 represents Sarepta Therapeutics' commitment to expanding treatment options for those affected by Duchenne muscular dystrophy, emphasizing personalized healthcare solutions.

  • ELEVIDYS
  • As an adeno-associated virus-based gene therapy, ELEVIDYS is focused on treating ambulatory pediatric patients aged 4 through 5 years with Duchenne, who have a confirmed mutation in the Duchenne gene. This gene therapy approach marks a significant advancement in treating genetic disorders, providing hope for younger patients and their families.

  • SRP-5051
  • Sarepta is also at the frontier of developing next-generation treatments with SRP-5051, a peptide conjugated PMO (phosphorodiamidate morpholino oligomer) that specifically binds exon 51 of dystrophin pre-mRNA. This therapeutic development underscores the company's ongoing commitment to innovation in drug development and personalized medicine for Duchenne muscular dystrophy.

  • SRP-9003
  • This gene therapy program is aimed at addressing limb-girdle muscular dystrophies (LGMD), another group of rare genetic disorders. Through SRP-9003, Sarepta Therapeutics is expanding its reach beyond Duchenne, demonstrating its broad commitment to tackling a wide range of rare genetic conditions.

Contact Information

Address: 215 First Street
Phone: 617 274 4000